Bio Protocol, an innovative startup focused on decentralized science, has successfully secured $6.9 million in funding to advance its AI-driven approach to biotech research.
The funding round included participation from notable investors such as Maelstrom Fund and Animoca Brands, both recognized for their investments in technology-forward ventures.
Instead of relying on traditional academic or pharmaceutical models, Bio Protocol is pioneering a novel system that combines AI technology, blockchain infrastructure, and community involvement. This integrated approach aims to accelerate scientific discoveries, particularly in crucial fields like drug development.
Did you know?
Subscribe – We publish new crypto explainer videos every week!
Copy Trading Guide for Beginners (ANIMATED EXAMPLES)
Arthur Hayes, the founder of Maelstrom Fund, views Bio Protocol as a transformative tool, suggesting that the platform has the potential to revolutionize the scientific research landscape by creating an entirely new marketplace.
A core element of Bio Protocol’s strategy involves “BioAgents,” which are autonomous AI-powered tools designed to recommend experiments and manage on-chain operations. These intelligent agents are capable of facilitating direct fundraising from interested supporters, enabling researchers to commence projects without enduring the often prolonged waiting periods associated with traditional grant applications or industry partnerships.
To ensure transparency and accountability, all platform activities will be securely recorded on a blockchain, providing an immutable and verifiable record of contributions.
The platform also incorporates token-based mechanisms, facilitating digital ownership of research findings, rewarding loyal participants, and implementing staking systems to align the interests of scientists, investors, and community members.
In other news, Helius Medical Technologies recently unveiled plans to establish a $500 million reserve using Solana. Want to know more? Dive into the details here.